Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).

Nick Pavlakis, Federica Grosso, Nicola L Steele, Anna K Nowak, Silvia Novello, Sanjay Popat, Laurent Greillier, Martin Reck, Tom John, Paul Taylor, Natasha B Leighl, Giovanni Luca Ceresoli, Jens Benn Sørensen, David Planchard, Brett Gordon Maxwell Hughes, Julien Mazieres, Mark A Socinski, Ute von Wangenheim, Jose Barrueco, Giorgio V Scagliotti